Castle Creek Biosciences, Inc. (CCBS)

Castle Creek Biosciences was planning to go public, but the IPO has been withdrawn.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Data will show when the stock starts trading.
Market Cap n/a
Revenue (ttm) n/a
Net Income (ttm) -32.75M
Shares Out n/a
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About CCBS

Castle Creek Biosciences is a clinical-stage cell and gene therapy company focused on developing and commercializing disease-modifying therapies for patients suffering from rare diseases for which there is a lack of available treatment options. Our proprietary platform serves as the foundation for developing personalized, targeted and redosable cell-based gene therapy product candidates. At present, our novel in-house manufacturing process entails collecting minimally invasive skin biopsies from patients, and transducing fibroblast cells with a... [Read more...]

Industry Pharmaceutical Preparations
Founded 2015
CEO Matthew Gantz
Employees 53
Stock Exchange NASDAQ
Ticker Symbol CCBS
Full Company Profile

Financial Performance

Financial Statements


Rare disease biotech Castle Creek Biosciences files for a $100 million IPO

Castle Creek Biosciences, a Phase 3 biotech developing cell-based gene therapies for rare diseases, filed on Friday with the SEC to raise up to $100 million.

1 year ago - NASDAQ

Castle Creek Biosciences IPO Registration Document (S-1)

Castle Creek Biosciences, Inc. has filed to go public with an IPO on the NASDAQ.

1 year ago - SEC